Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model

Anti-Cancer Drugs

Volumn 12, Issue 9, 2001, Pages 735-740

  Mohammad, Ramzi M ^a   Adsay, N Volkan ^a   Philip, Philip A ^a   Pettit, George R ^b   Vaitkevicius, Vainutis K ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Auristatin PE; Bryostatin 1; PANC 1; Pancreatic tumor line; SCID mice; Xenograft

Indexed keywords

AURISTATIN PE; BRYOSTATIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; SCID MOUSE; SIDE EFFECT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; FEMALE; HUMANS; LACTONES; MACROLIDES; MICE; MICE, SCID; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034783334     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200110000-00005     Document Type: Article

References (21)

1. Cancer statistics, 1995
2. Carcinoma of the pancreas. 50 years of surgery
3. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
4. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents
5. Propagation of Waldenstrom's-macroglobulinemia cells in vitro and in severe combined immune deficient mice: Utility as a preclinical drug screening model
6. Differential effects of bryostatin 1 on human non-Hodgkin's B lymphoma cell lines
7. Isolation and structure of Bryostatin 1
8. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma
9. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
10. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications
11. Dolastatin 10, a powerful cytostatic peptide derived from a murine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid-binding domain
12. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma
13. Discovery of solid tumor activity agents using a soft-agar-colony-formation disk-diffusion-assay
14. Tumor suppression by p21 WAF1
15. P53-independent induction of p21 WAF1 pathway is preserved during tumor progression
16. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
17. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh
18. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells
19. Sequential treatment of human chronic lymphocytic leukemia with Bryostatin 1 followed by 2-chlorodeoxyadenosine: Preclinical studies
20. Establishment of human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents
21. An orthotopic model of human pancreatic cancer in SCID-mice: Potential application for preclinical studies